{
    "clinical_study": {
        "@rank": "131127", 
        "arm_group": [
            {
                "arm_group_label": "study group", 
                "arm_group_type": "Experimental", 
                "description": "Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20"
            }, 
            {
                "arm_group_label": "control", 
                "arm_group_type": "Active Comparator", 
                "description": "Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20"
            }
        ], 
        "brief_summary": {
            "textblock": "Due to the radiosensitivity of the lung, radiation-induced and chemotherapy-induced\n      pneumonitis and pulmonary fibrosis are frequent happened following cancer therapy. It not\n      only compromise cancer treatment, but also influence patient's life qualities and even\n      death. there are no specific treatment modalities for this treatment-induced complication.\n      Bevasizumab (Avastin), a VEGF inhibitor, can attenuate serum high expression VEGF and\n      pulmonary permeability, maybe effective in the control acute pulmonary fibrosis. Patients\n      will be randomized to receive Bevasizumab (7mg/kg iv) on day one and 21, followed by\n      Dexamethasone \uff0810mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20) or Dexamethasone alone.\n      The thoracic CT, plasma TNF-a, IL-6, VEGF and C-reactive protein are accessed on before\n      treatment, 24 hours after Bevasizumab, 7 days, 4 and 8 weeks. the target sample size is 30\n      cases."
        }, 
        "brief_title": "Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Fibrosis", 
                "Pulmonary Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  clinical diagnosed cancer treatment-induced acute pulmonary fibrosis\n\n        Exclusion Criteria:\n\n          -  chronic pulmonary fibrosis and infection-induced pulmonary fibrosis\n\n          -  active bleeding\n\n          -  uncontrolled high blood pressure\n\n          -  unstable systemic disease\n\n          -  prior exposure to VEGF inhibitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01917877", 
            "org_study_id": "QCH-20030801"
        }, 
        "intervention": [
            {
                "arm_group_label": "study group", 
                "description": "Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20", 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin (Genentech/Roche)"
            }, 
            {
                "arm_group_label": "control", 
                "description": "Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20", 
                "intervention_name": "Dexamethasone", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "Bevacizumab", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Becacizumab", 
            "pulmonary fibrosis", 
            "irradiation", 
            "chemotherapy"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "location": {
            "contact": {
                "last_name": "youxin ji, md", 
                "phone": "86-532-68665078"
            }, 
            "facility": {
                "address": {
                    "city": "Qingdao", 
                    "country": "China", 
                    "state": "Shandong", 
                    "zip": "266042"
                }, 
                "name": "Qingdao Central Hospital"
            }, 
            "investigator": {
                "last_name": "youxin ji, md", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Bevasizumab in the Management of Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis", 
        "overall_contact": {
            "email": "ji6677@gmail.com", 
            "last_name": "youxin ji, md", 
            "phone": "86532-68665078"
        }, 
        "overall_official": {
            "affiliation": "Qingdao Central Hospital", 
            "last_name": "youxin ji, md", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "pulmonary function", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01917877"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "thoracic CT scan", 
            "safety_issue": "No", 
            "time_frame": "up to 8 weeks"
        }, 
        "source": "Qingdao Central Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Qingdao Central Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}